Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1046 in Malignant Solid Tumors
NCT03917381Phase 2Terminated
- Sponsor
- Genmab
- Start
- May 2019
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of acasunlimab in solid tumor, non-small cell lung cancer (NSCLC), endometrial cancer (EC) and 4 more (5 arms), sponsored by Genmab. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-emergent Adverse Events and 1 more. Started May 2019; status: terminated.
02
Drugs
acasunlimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)endometrial cancer (EC)urothelial carcinoma (UC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03917381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917381.